pargyline has been researched along with donepezil in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (86.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, J; Chen, X; Huang, L; Li, X; Sun, Y | 1 |
| Altomare, CD; Carotti, A; Carrupt, PA; Catto, M; Denora, N; Farina, R; Gadaleta, D; Mendez-Alvarez, E; Muncipinto, G; Nicolotti, O; Nurisso, A; Passos, CS; Pisani, L; Soto-Otero, R | 1 |
| Jiang, N; Kong, LY; Lan, JS; Li, F; Wang, J; Wang, X; Wang, ZM; Wu, JJ; Xie, SS | 1 |
| Altomare, CD; Carotti, A; Catto, M; Cellamare, S; Denora, N; Farina, R; Iacobazzi, RM; Mangiatordi, GF; Nicolotti, O; Pisani, L; Siragusa, L; Soto-Otero, R | 1 |
| Ding, Y; Hou, JW; Kang, P; Lan, JS; Liu, Y; Xie, SS; Zhang, T; Zhang, XY | 1 |
| Dong, SN; Gong, Q; Li, J; Li, XK; Liu, WW; Mao, F; Tang, Y; Wang, H; Wang, TD; Xu, YX; Zhang, HY; Zhu, J | 1 |
| Cai, P; Kong, LY; Li, F; Liu, QH; Wang, XB; Wu, JJ; Yang, XL | 1 |
| Bajaj, B; Dwivedi, AR; Kumar, B; Kumar, V; Mehta, D; Parkash, J; Prashar, V; Saini, S | 1 |
| Andrys, R; Capek, J; Handl, J; Hrabinova, M; Janockova, J; Kobrlova, T; Korabecny, J; Marco-Contelles, JL; Mezeiova, E; Micankova, P; Muckova, L; Nepovimova, E; Pejchal, J; Rousar, T; Simunkova, M; Soukup, O; Valko, M | 1 |
| Huang, M; Jiang, N; Kong, LY; Lan, JS; Wang, XB; Yin, FC | 1 |
| Bautista-Aguilera, OM; Esteban, G; Fernández Fernández, AP; Herrero, R; Inokuchi, T; Iriepa, I; Marco-Contelles, J; Moraleda, I; Ojima, M; Romero, A; Samadi, A; Soriano, E; Unzeta, M; Wang, L; Youdim, MB | 1 |
15 other study(ies) available for pargyline and donepezil
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Electrophorus; Humans; Isoflavones; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Swine; Tacrine | 2013 |
Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.
Topics: Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Coumarins; Dogs; Drug Design; Humans; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Permeability; Protein Conformation; Rats; Structure-Activity Relationship | 2015 |
Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line, Tumor; Cholinesterase Inhibitors; Cholinesterases; Coumarins; Donepezil; Dose-Response Relationship, Drug; Drug Design; Eels; Humans; Indans; Models, Molecular; Molecular Structure; Molecular Targeted Therapy; Piperidines; Structure-Activity Relationship | 2016 |
Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.
Topics: Acetylcholinesterase; Animals; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Coumarins; Dogs; Dose-Response Relationship, Drug; Humans; Madin Darby Canine Kidney Cells; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidative Stress; Solubility; Structure-Activity Relationship; Water | 2016 |
Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; PC12 Cells; Protein Aggregates; Pyridinium Compounds; Rats; Structure-Activity Relationship | 2017 |
Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognitive Dysfunction; Dose-Response Relationship, Drug; Drug Discovery; Humans; Imidazoles; Mice; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Propylamines; Pyrimidines; Rats; Scopolamine; Structure-Activity Relationship; Thiourea | 2018 |
Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer's disease.
Topics: | 2017 |
Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase.
Topics: Acetylcholinesterase; Alkynes; Alzheimer Disease; Catalytic Domain; Cell Line, Tumor; Cholinesterase Inhibitors; Drug Design; Humans; Kinetics; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pyrimidines; Structure-Activity Relationship | 2019 |
2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Drug Design; Humans; Naphthoquinones; Structure-Activity Relationship | 2021 |
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
Topics: | 2020 |
Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Chelating Agents; Cholinesterase Inhibitors; Donepezil; Hep G2 Cells; Humans; Hydroxyquinolines; Indans; Male; Memory; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Piperidines; Propylamines; Rats | 2014 |